An independent shop owner blamed the growing use of NHS-funded weight-loss injections for a recent slump in sales, arguing that the policy is having unintended consequences for specialist retailers.
Mark Simonelli, recently took over the running of Larger Men’s Clothing on Chelmsford’s Moulsham Street, he said trading conditions have become increasingly difficult. The outsize clothing shop sits among a cluster of independent retailers, but Mr Simonelli says footfall and demand have dropped sharply in recent weeks.
He believes weight loss jabs are contributing to his failing business (Image: Getty)
Mr Simonelli told i-paper that weight-loss injections are now a significant factor behind the slowdown. “It has been absolutely rubbish these last few weeks,” he said.
“I think there are several things going on, but one is the NHS and anti-obesity jabs encouraging these guys to come down in size. Don’t get me wrong, it’s great for them and the right thing to do, but it’s not particularly good news for my line of business.”
The comments come as the NHS expands access to prescription weight-management injections as part of its Prevention Programme, aimed at tackling obesity-related conditions such as type 2 diabetes, heart disease and high blood pressure.
The two main medicines currently approved for NHS use are tirzepatide, sold under the brand name Mounjaro, and semaglutide, marketed as Wegovy.
Both are injected once a week and work by reducing appetite and helping patients feel fuller for longer.
They are recommended by the National Institute for Health and Care Excellence (NICE) only for eligible adults living with obesity who also have weight-related health problems.
To qualify, patients must meet strict criteria based on body mass index (BMI) and existing health conditions, and must also commit to dietary changes and regular physical activity alongside the medication.
The NHS says the injections are not a “quick fix” and are provided with wraparound care, including support from dietitians and other healthcare professionals. The medicines are not recommended for pregnant or breastfeeding women, or those with certain medical conditions, and patients are closely monitored for side effects.
Supporters argue the programme could transform public health outcomes and reduce long-term strain on the NHS.
However, Mr Simonelli said the rapid cultural shift around weight loss has caught some niche retailers off guard. Businesses like his, which cater specifically to larger sizes, rely on a steady customer base that may now be shrinking.
